Michelle Arkin chairs the Department of Pharmaceutical Chemistry at UC San Francisco. Her research focuses on the development of drug-like molecules that alter important biological processes. These biological processes often involve complex networks of proteins that interact directly with each other; yet protein-protein interactions are difficult to target with conventional small molecules. Join us for on a briefing on the latest results from her lab.
Where & When
Zoom Webinar
Thursday, May 5, 2022, 1:00 to 2:00 PM PT
About the Speaker
Michelle Arkin’s lab develops innovative approaches to screen for chemical tools and drug leads, using biophysical approaches like fragment-based drug discovery and biological approaches including high-content imaging. Their goal is to demonstrate ‘druggability’ of new target classes and to use their compounds to discover new targets for drug discovery. Areas of interest include protein-protein interactions, allosteric and scaffolding sites in enzymes, focusing on diseases of aging like cancer and neurodegeneration. Michelle is Co-Director of the UCSF Small Molecule Discovery Center, a collaborative research and core lab that includes a high-throughput screening facility and medicinal chemistry. She is co-founder of Elgia Therapeutics and Ambagon Therapeutics.